This is just one more reason I am glad I am out of the "rat race" that I once loved. It saddens me the 360 degrees these companies have come from being respectable, educational, beneficial companies to ones who will stoop at anything to generate a buck and appeal to their investors on Wall Street - when I left in 2007 after 18 years, our meetings didn't consist of disease state knowledge or patient education anymore, they were: We are slipping and our INVESTORS aren't happy - we need to sell to make money - NOT help people ... they have forgotten this is about a variety of PEOPLE - doctors, patients of all ages, researchers, making people well or improving quality of life - it is not about the all mighty dollar. We will all one day be SICK I don't care if you are the CEO making millions you will one day NEED medical care. Your family will need care - don't they want that to be the very best possible option? Apparently not as you can tell from another Wyeth Pharma story: (they will soon be part of Pfizer I understand ?)
Canadian named in HRT scandal
MIKE DERER/AP FILE PHOTO
The headquarters of pharmaceutical company Wyeth is seen in this file photo.
A top Canadian researcher studying hormone replacement therapy was part of a ghostwriting scheme paid for by drug giant Wyeth Pharmaceuticals to promote its products, court documents obtained by the Toronto Star indicate.
The article in question appeared in the April 2000 edition of the Journal of the American Geriatrics Society and listed McGill University psychology professor Barbara Sherwin as author.
It argued that estrogen could help treat memory loss in older patients, while offering other benefits.
Sherwin is the first Canadian implicated in an ongoing scandal in the United States, where court documents ˆ unsealed recently after a successful motion by The New York Times and the journal PLoS Medicine ˆ have lifted the veil on the extent of ghostwriting in the pharmaceutical industry.
The university is investigating.
"McGill University is committed to the highest standards of honesty and integrity in research and scholarship and takes substantiated allegations of research misconduct very seriously," said provost Anthony C. Masi in a statement yesterday.
"The university has an established process for investigating and dealing with such allegations, (and) will look into this matter and take appropriate action."
Sherwin's article examined treatments for memory loss in aging patients. It favoured estrogen, used in hormone replacement therapy, saying the hormone could also help prevent cardiovascular disease and osteoporosis, as well as reduce the risk of colorectal cancer and "all-cause mortality in postmenopausal women."
"Since estrogen has been used for nearly 60 years, its effective dosages, side effects, and influences on other organ systems are well known," the study says, describing estrogen as "relatively safe."
The study, a copy of which remains in the stacks of the University of Toronto's medical school library, lists Sherwin as the sole author. But court documents now indicate that New Jersey ghostwriting firm DesignWrite, hired by Wyeth to promote its products, actually penned the article.
The danger of ghostwriting, said James Szaller, a Cleveland lawyer leading a large class-action suit against Wyeth, is that doctors rely on such articles when caring for their patients.
"It puts patients at risk, and doctors are relying on marketing materials and not truly clinical studies or unbiased reviews of the medical literature," he said. "It's insane."
Wyeth has defended the hormone articles as scientifically sound, saying they were subjected to rigorous reviews from outside experts. It has also begun to involve academics earlier in the process and to require that its financial involvement and the use of outside writers be acknowledged.
Doubts were already being raised about hormone replacement therapy by the time Sherwin's article appeared. In 2002, two U.S. studies linked the therapy to breast cancer, ovarian cancer, heart disease, strokes and blood clots. Other studies found links to dementia.
Sherwin declined comment, but issued a statement expressing regret for working with DesignWrite.
"I wrote a portion of the article, but not all of it, although only my name was listed as its author. Other parts of that article were written with the assistance of DesignWrite, a firm which, it turns out, was employed by a pharmaceutical manufacturer to assist in the development of academic articles," she said in the email statement.
"I made an error in agreeing to have my name attached to that article without having it made clear that others contributed to it. It is an error I regret and which had never occurred before or since. I received no remuneration for the article in question. I believe the article, which was peer-reviewed, represented sound and thorough scholarship and in no way could be construed as promotion for any particular product or company."
Szaller, who for four years has sifted through internal DesignWrite documents, said Sherwin seems to have offered "a fair amount of editing" suggestions to the writers, compared with others working with DesignWrite.
"There are some who simply seemed to glance at it and make one- or two-word changes," he said.
Sherwin has been a leading Canadian researcher on the relationship between estrogen and memory loss for more than 20 years.
Shortly after the article was published, she received a prestigious James McGill Professor award, which recognizes "a senior scholar's status as outstanding and original researcher of world-class caliber." In 2007, Sherwin was appointed Canada Research Chair in Hormones, Brain and Cognition, which garnered McGill federal funding of $200,000 annually for seven years. Last year she was granted $70,089 by the federally funded Canadian Institutes of Health Research for a four-year study on "estrogen and cognitive aging in women."
Court documents released to the Star indicate DesignWrite penned Sherwin's article and faxed it to her 18 months prior to its publication, asking her to "review the enclosed outline."
"Enclosed is the draft of the review paper, 'Age-associated memory impairment: potential pharmacological treatment options' that we discussed in June," wrote Karen Mittleman, senior medical writer at DesignWrite, in a letter to Sherwin from October 1998.
The documents, given to the Star this week by Szaller, were put online yesterday by PloS, a journal of the Public Library of Science.
The article itself had been written the preceding summer by freelancer Fran Karo. No credit was given to DesignWrite, Karo, Mittleman or any others for their work.
Some of the documents appear to be dated January 2005, when they were obtained in an Arkansas lawsuit against Wyeth. In a deposition of May 2, 2006, Mittleman said the 2005 date was computer-generated, but the documents date from the late 1990s.
DO YOU TRUST THE DRUGS YOU ARE TAKING? If no, why not? Do you believe your doctor has your best interest in mind? (I'm not advocating stopping meds - I believe they are beneficial; sadly I probably keep all the companies in business on my own with my multiple autoimmune struggles AND they help but I do question taking new ones when there isn't anything wrong with the older, cheaper ones...I just ask questions, I'm a HEALTHY SKEPTIC)